# Association between missense variants of uncertain significance in the CHEK2 gene and hereditary breast cancer: a cosegregation and bioinformatics analysis

**Authors:** Natalia Alonso, Sebastián Menao, Rodrigo Lastra, María Arruebo, María P. Bueso, Esther Pérez, M. Laura Murillo, María Álvarez, Alba Alonso, Soraya Rebollar, Mara Cruellas, Dolores Arribas, Mónica Ramos, Dolores Isla, Juan José Galano-Frutos, Helena García-Cebollada, Javier Sancho, Raquel Andrés

PMC · DOI: 10.3389/fgene.2023.1274108 · Frontiers in Genetics · 2024-02-27

## TL;DR

This study examines how CHEK2 gene variants, especially those of uncertain significance, are linked to hereditary breast cancer and uses bioinformatics to assess their potential harm.

## Contribution

The study provides new evidence on the pathogenicity of CHEK2 variants of uncertain significance using cosegregation and bioinformatics analysis.

## Key findings

- Nine CHEK2 gene variants were identified in 10 breast cancer patients, including two pathogenic and seven variants of uncertain significance.
- Bioinformatics analysis predicted pathogenicity for six of the variants of uncertain significance.
- A positive cosegregation study was found in one of two families analyzed.

## Abstract

Inherited mutations in the CHEK2 gene have been associated with an increased lifetime risk of developing breast cancer (BC). We aim to identify in the study population the prevalence of mutations in the CHEK2 gene in diagnosed BC patients, evaluate the phenotypic characteristics of the tumor and family history, and predict the deleteriousness of the variants of uncertain significance (VUS). A genetic study was performed, from May 2016 to April 2020, in 396 patients diagnosed with BC at the University Hospital Lozano Blesa of Zaragoza, Spain. Patients with a genetic variant in the CHEK2 gene were selected for the study. We performed a descriptive analysis of the clinical variables, a bibliographic review of the variants, and a cosegregation study when possible. Moreover, an in-depth bioinformatics analysis of CHEK2 VUS was carried out. We identified nine genetic variants in the CHEK2 gene in 10 patients (two pathogenic variants and seven VUS). This supposes a prevalence of 0.75% and 1.77%, respectively. In all cases, there was a family history of BC in first- and/or second-degree relatives. We carried out a cosegregation study in two families, being positive in one of them. The bioinformatics analyses predicted the pathogenicity of six of the VUS. In conclusion, CHEK2 mutations have been associated with an increased risk for BC. This risk is well-established for foundation variants. However, the risk assessment for other variants is unclear. The incorporation of bioinformatics analysis provided supporting evidence of the pathogenicity of VUS.

## Linked entities

- **Genes:** CHEK2 (checkpoint kinase 2) [NCBI Gene 11200]
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** CHEK2 (checkpoint kinase 2) [NCBI Gene 11200] {aka CDS1, CHK2, HuCds1, LFS2, PP1425, RAD53}
- **Diseases:** BC (MESH:D001943), tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10927753/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10927753/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC10927753/full.md

---
Source: https://tomesphere.com/paper/PMC10927753